Evexomostat (SDX-7320) Reduces Obesity-Driven Tumor Growth

This publication from SynDevRx examines the dual anti-obesity and anti-tumor effects of Evexomostat (SDX-7320), a METAP2 inhibitor evaluated in diet-induced obese mouse and rat models. Using Next-Generation Metabolomics from Panome Bio, the study reveals distinct metabolic signatures that differentiate SDX-7320 from traditional weight-loss agents, aligning with its observed suppression of obesity-accelerated tumor growth. Integrated metabolic and transcriptomic insights demonstrate how SDX-7320 influences systemic metabolism and intratumoral pathways, supporting its potential as a therapy for obesity-associated cancer progression.